10-K: Hinge Health's 2025 Annual Report: Growth Amidst Losses

Hinge Health reports significant revenue growth and member expansion in 2025, alongside a substantial net loss driven by IPO-related stock compensation.

Summary

• Hinge Health operates as a digital clinic for musculoskeletal (MSK) conditions, utilizing an AI-powered care model, wearable devices, and a multidisciplinary care team.
• The company's revenue increased by 51% to $587.86 million in 2025, up from $390.404 million in 2024, primarily driven by growth from existing clients.
• A net loss of $528.261 million was reported for 2025, a significant increase from a net loss of $11.933 million in 2024, largely due to $643.009 million in stock-based compensation expense related to IPO-triggered vesting.
• Gross profit rose by 56% to $468.222 million in 2025, with gross margin improving to 80% from 77% in 2024, attributed to efficiencies in care team and supply chain operations.
• Total operating expenses surged to $1,014.593 million in 2025 from $331.812 million in 2024, predominantly due to the stock-based compensation.
• The number of members grew to 782,890 in 2025 from 532,326 in 2024, and clients increased to 2,830 from 2,256 over the same period.
• LTM (Last Twelve Months) average eligible lives reached 20.105 million in 2025, up from 15.747 million in 2024.
• LTM calculated billings increased to $671.418 million in 2025 from $467.504 million in 2024.
• The company completed its Initial Public Offering (IPO) in May 2025, raising $255.7 million in net proceeds, which were primarily used to cover employee taxes for RSU and PRSU settlements.
• A share repurchase program of up to $250.0 million was authorized on November 10, 2025, with $65.0 million repurchased by December 31, 2025.
• Hinge Health launched HingeSelect, a high-performance in-person provider network for MSK care, in 2025.
• The company's AI-powered motion tracking technology, TrueMotion, is estimated to have reduced human care team hours associated with traditional physical therapy by approximately 97% in 2025.
• As of December 31, 2025, the company held $208.0 million in cash and cash equivalents and $269.0 million in marketable securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative report. While operational growth and revenue are strong, the substantial net loss driven by IPO-related stock compensation and the accumulated deficit indicate significant ongoing investment and a lack of GAAP profitability, which could concern some investors.

Positives

• Revenue increased by a robust 51% to $587.86 million in 2025, demonstrating strong top-line growth.
• Gross margin improved to 80% in 2025 from 77% in 2024, indicating increased operational efficiencies in care team and supply chain.
• The client base expanded significantly to 2,830 in 2025 from 2,256 in 2024, and members grew to 782,890 from 532,326, showing strong market penetration and adoption.
• Net cash provided by operating activities was $171.441 million in 2025, a substantial improvement from $49.002 million in 2024.
• Free cash flow increased to $179.604 million in 2025 from $45.229 million in 2024, reflecting improved liquidity from operations.
• The company maintains a high 12-month client retention rate of 97% as of December 31, 2025, indicating strong client satisfaction and recurring business.
• Strategic partnerships with over 60 entities, including the five largest national health plans and top three PBMs, provide a scalable go-to-market model.
• Continuous innovation is evident with the launch of HingeSelect (in-person MSK care network) in 2025, and prior introductions of women's pelvic health, fall prevention programs, the Enso device, and TrueMotion AI technology.
• The AI-powered platform is highly efficient, estimated to have reduced human care team hours by approximately 97% in 2025 while maintaining high member satisfaction.
• The company holds significant intellectual property, with 40 issued patents and 88 pending patent applications for TrueMotion, and 8 issued and 12 pending for Enso as of December 31, 2025.

Negatives

• Reported a substantial net loss of $528.261 million in 2025, a significant increase from $11.933 million in 2024, primarily due to non-cash stock-based compensation.
• The accumulated deficit reached $1.05 billion as of December 31, 2025, indicating a history of unprofitability.
• Total operating expenses more than tripled in 2025 to $1,014.593 million, largely driven by the $643.009 million in stock-based compensation expense.
• Cash and cash equivalents decreased from $300.785 million in 2024 to $207.995 million in 2025.
• A significant portion of revenue (82% in 2025) is derived from client contracts through a limited number of partners, with the top three partners accounting for 17.5%, 13.7%, and 10.5% of revenue, posing a concentration risk.
• The company does not intend to pay dividends for the foreseeable future, meaning investor gains will depend solely on stock price appreciation.

Risks

• The company has a history of net losses and anticipates increasing expenses, with no guarantee of achieving or maintaining profitability.
• Failure to effectively manage rapid growth could strain operational and financial resources and adversely affect business.
• Inability to successfully execute growth initiatives, especially in new markets like fully-insured health plans, Medicare Advantage, and international expansion, which operate under different financial dynamics.
• A limited operating history makes it difficult to evaluate future prospects and accurately predict results of operations.
• Results of operations have fluctuated and may continue to fluctuate, potentially leading to stock price decline if analyst or investor expectations are not met.
• Inability to attract new clients, retain existing clients, renew agreements on favorable terms, or achieve performance guarantees could materially adversely affect financial condition.
• Substantial reliance on a limited number of health plans and partners; loss or renegotiation of these relationships could significantly impact revenue and business.
• Increasing reliance on AI and machine learning technologies exposes the company to risks including development/deployment challenges, regulatory uncertainties, potential third-party claims, and adverse public perception.
• Inability to establish, maintain, protect, and enforce intellectual property rights or prevent unauthorized use, or becoming subject to infringement claims, could harm brand and competitive position.
• Operating in a highly regulated industry (healthcare, data privacy, medical devices, AI) means changes in regulations or their implementation could increase compliance costs and liabilities.
• The FDA may modify enforcement policies for medical software, potentially subjecting the company's programs to extensive regulatory requirements and increased costs.
• The price of Class A common stock may be volatile or decline regardless of operating performance, leading to substantial losses for investors.
• The dual-class common stock structure concentrates voting control with Founders and Series E preferred stockholders, limiting the influence of other shareholders on corporate matters.
• Shares of Series E preferred stock, held by Tiger Global, have preference rights (e.g., liquidation preference of $200.0 million) and anti-dilution adjustments that could impact the value of Class A common stock.
• Sales of a substantial amount of Class A common stock by existing security holders could cause the market price to decline.
• Anti-takeover provisions in corporate documents and Delaware law could delay or prevent acquisition attempts.
• Exposure to medical liability claims against the company and its affiliated professional entities, which could result in significant expenses and damages not fully covered by insurance.
• Subject to regular and special audit requirements, as well as inquiries or investigations by governmental agencies or regulators, particularly for HingeSelect, which could lead to sanctions or fines.
• Legal challenges to the ability to offer the platform and programs in certain jurisdictions due to evolving laws governing remote healthcare and the practice of medicine/physical therapy.
• Uncertainty regarding the applicability of sales, use, and other tax laws or regulations, potentially leading to additional tax liability.
• International operations expose the company to exchange rate fluctuations and other currency risks.
• Estimates of market opportunity and forecasts of market growth, as well as operational metrics, may prove inaccurate.
• Uncertain or unfavorable conditions in the industry or global economy (e.g., inflation, interest rates, conflicts, natural disasters) could limit business growth.
• Business operations are subject to interruption by natural disasters, power shortages, cybersecurity attacks, and other events beyond control.
• The company's insurance strategy may not be adequate to protect against all business risks.
• Management has limited experience in operating a public company, which could lead to increased costs and diversion of time to compliance.
• Failure to establish and maintain an effective system of disclosure controls and procedures and internal control over financial reporting could adversely affect financial reporting accuracy.
• As an emerging growth company, compliance with reduced reporting requirements may make Class A common stock less attractive to some investors.

Future Outlook

The company anticipates increasing expenses in the foreseeable future as it invests further in business growth, member and client acquisition, partner engagement, hiring, and platform development. It plans to continue expanding its client base in core markets and internationally, with further global footprint expansion expected in 2026. The company is committed to continuous innovation, developing new programs, products, and capabilities based on a promising product roadmap. Seasonality in calculated billings and free cash flow is expected to continue, with billings typically highest in the second quarter. The company expects to fund share repurchases with existing cash and cash equivalents and cash from operations, and intends to utilize the extended transition period for new accounting standards as an emerging growth company.

Management Comments

• Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care.
• We believe that we grow efficiently because of our scalable, repeatable go-to-market model.
• According to our estimates based on data from 2025, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 97%.
• We believe we are well positioned for continued growth.
• We believe the thoughtful development of technology can radically improve experiences, outcomes, and costs in healthcare while ensuring consistent care regardless of income level or geography.
• We believe our AI approach is a differentiator, allowing our care team more time to connect with members in the most high impact way.
• We believe our business is resilient even in difficult macroeconomic conditions given our focus on delivering positive outcomes for our members and ROI for our clients.

Industry Context

StockSavvy.ai notes that Hinge Health operates in the rapidly evolving and competitive digital health and musculoskeletal (MSK) care markets. The company faces competition from other digital platforms like Sword Health Technologies, Inc. (which acquired Kaia Health Software, Inc. in January 2026), Omada Health, Inc., and Vori Health, Inc., as well as from health plans and health systems developing their own solutions. Hinge Health's strategy of leveraging AI, expanding its program offerings (e.g., HingeSelect for in-person care), and focusing on employer and health plan partnerships aligns with broader industry trends towards integrated, technology-driven, and cost-effective healthcare solutions. The increasing regulatory scrutiny on AI in healthcare and data privacy is a significant industry-wide challenge.

Comparison to Industry Standards

• Hinge Health's platform is estimated to have reduced human care team hours associated with traditional physical therapy by approximately 97% in 2025, suggesting a significant efficiency advantage over conventional models.
• The company's 12-month client retention rate of 97% as of December 31, 2025, indicates strong performance in retaining business relationships, which is a key metric for subscription-based healthcare services and compares favorably to industry averages for SaaS and healthcare tech.
• The Enso device, an FDA-cleared electrical nerve stimulation technology, has demonstrated in randomized controlled trials (published in 2024) an increased likelihood of pain reduction versus exercise therapy alone and other transcutaneous electronic nerve stimulation, positioning it competitively against other pain relief solutions.
• Hinge Health competes with digital platforms such as Sword Health Technologies, Inc. (which acquired Kaia Health Software, Inc. in January 2026), Omada Health, Inc., and Vori Health, Inc., all vying for market share in the digital MSK care space by offering technology-driven solutions.

Management Changes

Corporate Governance

Legal Proceedings

• Not presently a party to any litigation that would individually or in aggregate have a material adverse effect on business, results of operations, or financial condition.
• Future litigation may be necessary to defend intellectual property rights, establish proprietary rights, or for other matters, which could be costly and divert management attention.
• Subject to regular or special audit requirements and inquiries/investigations by governmental agencies or regulators, particularly for HingeSelect, which could result in sanctions, fines, or changes to business practices.

Related Party Transactions

• Executive Chairman Gabriel Mecklenburg repaid a partial recourse promissory note of $2.2 million on February 4, 2025.
• CEO Daniel Perez repaid a partial recourse promissory note of $2.2 million on February 7, 2025.
• The former Chief Financial Officer repaid a partial recourse promissory note of $0.5 million on February 26, 2025.
• The company engages the law firm Perkins Coie LLP for legal services, incurring $1.7 million in fees in 2025 and $2.0 million in 2024. A sibling of the CEO is a partner at Perkins Coie LLP.

Stakeholder Impact

• Shareholders: The dual-class structure concentrates voting power with Founders and Series E preferred stockholders, potentially limiting the influence of Class A common stockholders. The Series E preferred stock has a liquidation preference and anti-dilution rights. The share repurchase program could influence stock price. IPO proceeds were primarily used for employee taxes, not direct company investment.
• Employees: A workforce reduction of approximately 160 people (10%) occurred in April 2024. The IPO triggered significant stock-based compensation expense for RSU/PRSU vesting. An Employee Stock Purchase Plan (ESPP) is available.
• Clients: Benefit from cost reductions in MSK care and positive member outcomes, supported by a high 97% client retention rate. The new HingeSelect offering provides end-to-end MSK care.
• Members: Receive personalized, AI-powered MSK care, including new programs for women's pelvic health and fall prevention, and access to the FDA-cleared Enso device for pain relief.
• Partners: Play a crucial role in the go-to-market strategy, facilitating client acquisition and implementation. However, the company's dependence on a limited number of large partners creates a concentration risk.
• Creditors: The liquidation preference of Series E preferred stock holders ranks above common stockholders in the event of liquidation.

Next Steps

• Further expand global footprint in 2026.
• Evaluate opportunities to expand beyond core self-insured employer market into additional government agencies and healthcare programs, such as Medicare and Medicaid.
• Continue to develop and invest in the platform to provide more value to members, clients, and partners.
• Continuously optimize targeting to maximize member enrollment.
• Upsell clients on the new HingeSelect offering.
• The board of directors may modify, suspend, or terminate the share repurchase program at its discretion.
• Continue to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) and related guidance.
• Assess and address the impact of the Illinois Physical Therapy Act amendment on business.
• Comply with FDA's Quality Management System Regulation (QMSR) expected to go into effect on February 2, 2026.
• Comply with California Consumer Privacy Act (CCPA) automated decision-making regulations by January 1, 2027.

Key Dates

Recommendation

Hinge Health demonstrates strong revenue growth and operational expansion, driven by innovative AI-powered solutions and strategic partnerships. However, the substantial net loss in 2025, primarily due to IPO-related stock compensation, and the accumulated deficit indicate significant ongoing investment and a lack of GAAP profitability, which could concern some investors. The dual-class share structure and dependence on key partners also present governance and business risks. While the long-term vision and market opportunity are compelling, the current financial performance and inherent risks suggest a 'hold' recommendation for seasoned investors, awaiting clearer signs of sustainable profitability and reduced reliance on non-cash expenses.

Keywords

Digital Health, Musculoskeletal Care, AI, Telehealth, Physical Therapy, Wearable Devices, Health Plans, Employers, SEC Filing, IPO, Stock Compensation, Corporate Governance, Risk Management, Healthcare Technology, Enso, TrueMotion, HingeConnect, HingeSelect, Delaware General Corporation Law, FDA, GDPR, HIPAA, CCPA